Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2R68E)

Drug Name
Ramipril Drug Info
Synonyms
Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
Indication
Disease Entry ICD 11 Status REF
Acute heart failure BD10-BD13 Approved [1]
Chronic heart failure BD1Z Approved [2]
Congestive heart failure BD10 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Stroke 8B20 Investigative [2]
Therapeutic Class
Antihypertensive Agents
Cross-matching ID
PubChem CID
5362129
ChEBI ID
CHEMBL1168
CAS Number
CAS 87333-19-5
TTD Drug ID
DM2R68E
VARIDT Drug ID
DR00031
INTEDE Drug ID
DR2648
ACDINA Drug ID
D00582

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Angiotensin-converting enzyme (ACE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enalapril DMNFUZR Congestive heart failure BD10 Approved [9]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [10]
Captopril DM458UM Chronic heart failure BD1Z Approved [11]
Benazepril DMH1M9B Hypertension BA00-BA04 Approved [12]
Moexipril DM26E4B Hypertension BA00-BA04 Approved [13]
Perindopril DMOPZDT Hypertension BA00-BA04 Approved [14]
Trandolapril DM4L6EU Chronic heart failure BD1Z Approved [15]
Fosinopril DM9NJ52 Chronic heart failure BD1Z Approved [16]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [17]
Enalaprilat DMFYAM1 Congestive heart failure BD10 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting HUMAN angiotensin-converting enzyme (ACE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Captopril DM458UM Chronic heart failure BD1Z Approved [6]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [19]
Drug(s) Transported By Peptide transporter 1 (SLC15A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [20]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [21]
Ampicillin DMHWE7P Acute epiglottitis Approved [22]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [23]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [24]
Cefazolin DMPDYFR Bacteremia 1A73 Approved [25]
Ceftriaxone DMCEW64 Acute gonococcal cervicitis Approved [26]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [21]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [23]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Peptide transporter 2 (SLC15A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [20]
Ampicillin DMHWE7P Acute epiglottitis Approved [27]
Enalapril DMNFUZR Congestive heart failure BD10 Approved [28]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [29]
Cefadroxil DMMC345 Bacterial infection 1A00-1C4Z Approved [30]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [27]
Valaciclovir DMHKS94 Genital herpes 1A94 Approved [31]
Cefaclor DMJXDGC Bacterial infection 1A00-1C4Z Approved [20]
Aminolevulinic acid hci DMS4BLQ Acne vulgaris ED80 Approved [32]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [33]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [34]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [35]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [36]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [37]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [38]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [39]
Epinephrine DM3KJBC Acute asthma CA23 Approved [40]
Chlorthalidone DM4DMBT Edema MG29 Approved [41]
Trandolapril DM4L6EU Chronic heart failure BD1Z Approved [42]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [5]
HUMAN angiotensin-converting enzyme (ACE) TTGFNPD ACE_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [7]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [8]

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 202392.
2 Ramipril FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6339).
4 ClinicalTrials.gov (NCT04366050) Ramipril for the Treatment of COVID-19. U.S. National Institutes of Health.
5 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
6 Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
7 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
8 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
9 Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
10 Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
11 Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
12 Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
13 Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
14 Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
15 Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
16 Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
17 Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
18 Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
19 Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.
20 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
21 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
22 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
23 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
24 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
25 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
26 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
27 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
28 Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
29 The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
30 Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
31 Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
32 PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
33 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
34 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
35 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
36 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
37 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
38 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
39 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
40 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
41 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
42 Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. J Clin Pharm Ther. 2006 Apr;31(2):139-47. doi: 10.1111/j.1365-2710.2006.00606.x.